Light-Controlled Molecular Switch Reactivates Dormant Cancer Cells, Making Them Vulnerable
ETH Zurich scientists have engineered a light-activated molecular switch that targets and destroys receptors keeping cancer cells dormant, forcing them back into a treatable state. This breakthrough could overcome one of cancer therapy's biggest challenges: dormant cells that hide from treatment.
What Happened
Some cancer cells evade treatment by entering a dormant state triggered by stress hormones. ETH Zurich scientists have created a light-controlled molecular switch that selectively destroys the receptors responsible for this survival mode. This innovation represents a significant advance in combating one of the most frustrating aspects of cancer therapy: cells that survive treatment by going into hibernation.
The Challenge
Cancer cells possess a remarkable survival strategy. When exposed to chemotherapy or other stressors, certain malignant cells enter a dormant, quiescent state where they essentially "go to sleep"—stopping growth and becoming invisible to most cancer treatments. These dormant cells can hide for months or years, eventually reawakening to cause relapse. This mechanism has long plagued oncologists and significantly limits cure rates for many cancer types.
The Solution
The ETH Zurich team developed a molecular switch activated by light that precisely targets the stress hormone receptors that trigger and maintain this dormant state. When activated by specific wavelengths of light delivered through minimally invasive means, the switch destroys these receptors, forcing dormant cancer cells to exit their protective hibernation and resume growth—making them vulnerable to existing chemotherapies and immune system attack.
Clinical Path Forward
Preliminary laboratory studies show the approach works effectively in cell cultures. The team is now optimizing the light delivery system for use in animal models, with plans for early-stage human trials within three years. If successful, this optogenetic approach could be combined with conventional treatments to dramatically improve cure rates for currently resistant cancers.